NO790384L - Fremgangsmaate for fremstilling av avgiftede preparater av cytostatika - Google Patents
Fremgangsmaate for fremstilling av avgiftede preparater av cytostatikaInfo
- Publication number
- NO790384L NO790384L NO790384A NO790384A NO790384L NO 790384 L NO790384 L NO 790384L NO 790384 A NO790384 A NO 790384A NO 790384 A NO790384 A NO 790384A NO 790384 L NO790384 L NO 790384L
- Authority
- NO
- Norway
- Prior art keywords
- salt
- chloroethyl
- sulfonic acid
- oxo
- dithiodialkane
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 239000000824 cytostatic agent Substances 0.000 title description 38
- 230000001085 cytostatic effect Effects 0.000 title description 33
- 238000002360 preparation method Methods 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims description 26
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 17
- 229960001101 ifosfamide Drugs 0.000 claims description 15
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims description 10
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 8
- 229960000875 trofosfamide Drugs 0.000 claims description 8
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- ZSZKJARKHWCBJK-UHFFFAOYSA-N 2-[[3-(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-yl]amino]ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCNP1(=O)OCCCN1CCCl ZSZKJARKHWCBJK-UHFFFAOYSA-N 0.000 claims description 5
- 229950008275 sufosfamide Drugs 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000001784 detoxification Methods 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 21
- 210000003932 urinary bladder Anatomy 0.000 description 18
- 239000002253 acid Substances 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 210000001635 urinary tract Anatomy 0.000 description 6
- 230000002152 alkylating effect Effects 0.000 description 5
- 235000014103 egg white Nutrition 0.000 description 5
- 210000000969 egg white Anatomy 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 150000003460 sulfonic acids Chemical class 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- COSZWAUYIUYQBS-UHFFFAOYSA-B hexapotassium hexasodium 3-carboxy-3-hydroxypentanedioate 2-hydroxypropane-1,2,3-tricarboxylate hydrate Chemical compound O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[K+].[K+].[K+].[K+].[K+].[K+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O COSZWAUYIUYQBS-UHFFFAOYSA-B 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000021962 pH elevation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000009120 supportive therapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LGBPWIAXPVUTMY-JLAZNSOCSA-N (2r)-3,4-dihydroxy-2-[(1s)-1-hydroxyethyl]-2h-furan-5-one Chemical compound C[C@H](O)[C@H]1OC(=O)C(O)=C1O LGBPWIAXPVUTMY-JLAZNSOCSA-N 0.000 description 1
- 229940006193 2-mercaptoethanesulfonic acid Drugs 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- 241000931365 Ampelodesmos mauritanicus Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MRIMWDXKBILRPB-UHFFFAOYSA-N O=P1NCCCO1 Chemical class O=P1NCCCO1 MRIMWDXKBILRPB-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- -1 mercapto compounds Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000008427 organic disulfides Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2806866A DE2806866C3 (de) | 1978-02-17 | 1978-02-17 | Verwendung von Salzen von Dithiodialkansulfonsäuren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO790384L true NO790384L (no) | 1979-08-20 |
Family
ID=6032295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO790384A NO790384L (no) | 1978-02-17 | 1979-02-07 | Fremgangsmaate for fremstilling av avgiftede preparater av cytostatika |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4218471A (el) |
| EP (1) | EP0003750B1 (el) |
| JP (1) | JPS6031810B2 (el) |
| AR (1) | AR219370A1 (el) |
| AT (1) | AT358163B (el) |
| CA (1) | CA1121727A (el) |
| DD (1) | DD141995A5 (el) |
| DE (1) | DE2806866C3 (el) |
| DK (1) | DK154609C (el) |
| EG (1) | EG14059A (el) |
| ES (1) | ES477630A1 (el) |
| FI (1) | FI790426A (el) |
| GR (1) | GR65642B (el) |
| HU (1) | HU182437B (el) |
| IE (1) | IE47788B1 (el) |
| IL (1) | IL56416A (el) |
| MC (1) | MC1251A1 (el) |
| MX (1) | MX6274E (el) |
| NO (1) | NO790384L (el) |
| PL (1) | PL213450A1 (el) |
| PT (1) | PT69237A (el) |
| ZA (1) | ZA79109B (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1185551B (it) * | 1985-04-15 | 1987-11-12 | Schering Spa | Composizioni farmaceutiche a base di acido mercaptoetansolfonico ad attivita' terapeutica,derivati salini organici dell'acido mercaptoetansolfonico utili per tali composizioni e relativo procedimento di preparazione |
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| ATE127018T1 (de) * | 1992-03-06 | 1995-09-15 | Fiutowski Zdzislaw | Pharmazeutische zusammensetzung mit antiviraler und antibakterieller wirkung. |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US6034126A (en) * | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
| DE102005008797A1 (de) * | 2005-02-25 | 2006-09-07 | Baxter International Inc., Deerfield | Trofosfamid-haltige Filmtabletten und Verfahren zu deren Herstellung |
-
1978
- 1978-02-17 DE DE2806866A patent/DE2806866C3/de not_active Expired
-
1979
- 1979-01-10 ZA ZA00790109A patent/ZA79109B/xx unknown
- 1979-01-11 GR GR58070A patent/GR65642B/el unknown
- 1979-01-11 IL IL56416A patent/IL56416A/xx not_active IP Right Cessation
- 1979-01-22 EP EP79100177A patent/EP0003750B1/de not_active Expired
- 1979-01-26 AR AR275322A patent/AR219370A1/es active
- 1979-01-30 IE IE157/79A patent/IE47788B1/en not_active IP Right Cessation
- 1979-02-02 MC MC791360A patent/MC1251A1/xx unknown
- 1979-02-06 US US06/009,625 patent/US4218471A/en not_active Expired - Lifetime
- 1979-02-06 AT AT88379A patent/AT358163B/de not_active IP Right Cessation
- 1979-02-07 NO NO790384A patent/NO790384L/no unknown
- 1979-02-08 FI FI790426A patent/FI790426A/fi unknown
- 1979-02-12 ES ES477630A patent/ES477630A1/es not_active Expired
- 1979-02-13 DD DD79211006A patent/DD141995A5/de not_active IP Right Cessation
- 1979-02-14 EG EG89/79A patent/EG14059A/xx active
- 1979-02-15 DK DK066079A patent/DK154609C/da not_active IP Right Cessation
- 1979-02-15 PT PT7969237A patent/PT69237A/pt unknown
- 1979-02-15 PL PL21345079A patent/PL213450A1/xx unknown
- 1979-02-15 MX MX797719U patent/MX6274E/es unknown
- 1979-02-16 HU HU79AA921A patent/HU182437B/hu not_active IP Right Cessation
- 1979-02-16 CA CA000321645A patent/CA1121727A/en not_active Expired
- 1979-02-17 JP JP54016770A patent/JPS6031810B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA1121727A (en) | 1982-04-13 |
| EP0003750A1 (de) | 1979-09-05 |
| DK154609C (da) | 1989-05-16 |
| IE790157L (en) | 1979-08-17 |
| EG14059A (en) | 1983-03-31 |
| MC1251A1 (fr) | 1980-01-14 |
| DD141995A5 (de) | 1980-06-04 |
| EP0003750B1 (de) | 1981-04-15 |
| ATA88379A (de) | 1980-01-15 |
| ZA79109B (en) | 1979-12-27 |
| MX6274E (es) | 1985-03-05 |
| DK66079A (da) | 1979-08-18 |
| DE2806866B2 (de) | 1980-05-29 |
| FI790426A (fi) | 1979-08-18 |
| US4218471A (en) | 1980-08-19 |
| ES477630A1 (es) | 1979-07-16 |
| IL56416A0 (en) | 1979-03-12 |
| JPS54140734A (en) | 1979-11-01 |
| PL213450A1 (el) | 1980-02-11 |
| DE2806866C3 (de) | 1981-02-12 |
| DK154609B (da) | 1988-12-05 |
| PT69237A (en) | 1979-03-01 |
| IL56416A (en) | 1983-11-30 |
| AR219370A1 (es) | 1980-08-15 |
| HU182437B (en) | 1984-01-30 |
| IE47788B1 (en) | 1984-06-13 |
| JPS6031810B2 (ja) | 1985-07-24 |
| GR65642B (en) | 1980-10-15 |
| AT358163B (de) | 1980-08-25 |
| DE2806866A1 (de) | 1979-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11311507B2 (en) | Enterically coated cysteamine, cystamine and derivatives thereof | |
| US4749572A (en) | Pharmaceutical preparations | |
| US4220660A (en) | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents | |
| US5006551A (en) | Composition for destroying malignant tumors | |
| BR0010257A (pt) | Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados | |
| CA2104868C (en) | Method and products for treating the eye | |
| NO790384L (no) | Fremgangsmaate for fremstilling av avgiftede preparater av cytostatika | |
| BR0010256A (pt) | Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kit de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários | |
| Morgan et al. | Successful renal transplantation in hyperoxaluria | |
| US6031006A (en) | Method of treating diabetic nephropathy | |
| CA1117015A (en) | Process for producing detoxified pharmaceutical products containing a cytostatically active alkylating agent | |
| JP2023137747A (ja) | ヨウ素化合物とコタラヒムブツエキスを含有する組成物 | |
| US20060063742A1 (en) | Method of treatment for or protection against lymphedema | |
| US3755567A (en) | Method for treating alcoholism |